Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.67 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.65 |
| ▸ | MAOB | P27338 | 10/20 | 0.62 |
| ▸ | MAOA | P21397 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA3 | P07451 | 1/20 | 0.62 |
| ▸ | CA4 | P22748 | 1/20 | 0.62 |
| ▸ | CA6 | P23280 | 1/20 | 0.62 |
| ▸ | CA7 | P43166 | 1/20 | 0.62 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28438618 | 0.88 | AR (0.68) | ARSLC16A3MAOBMAOAKDM4E | |
| SCHEMBL29724361 | 0.88 | AR (0.68) | ARSLC16A3MAOBMAOAKDM4E | |
| SCHEMBL238751 | 0.80 | AR (1.00) | ARMAOBMAOANPC1 | |
| SCHEMBL31379014 | 0.79 | GPR55 (0.49) | ARSLC16A3MAOBMAOANPC1 | |
| SCHEMBL93260 | 0.79 | SLC16A3 (1.00) | SLC16A3MAOBMAOAMEN1NPC1 | |
| SCHEMBL29066609 | 0.79 | SLC16A3 (0.70) | SLC16A3MAOBMAOAMEN1NPC1 | |
| SCHEMBL4648135 | 0.79 | SLC16A3 (0.66) | SLC16A3MAOBMAOAMEN1NPC1 | |
| SCHEMBL1093778 | 0.78 | MAOB (0.72) | SLC16A3MAOBMAOAMEN1NPC1 | |
| SCHEMBL28776464 | 0.78 | MAOB (0.67) | ARMAOBMAOANPC1ACHE | |
| SCHEMBL1712282 | 0.77 | MAOB (0.57) | SLC16A3MAOBMAOAMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091022-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING FATTY LIVER DISEASE | SHIONOGI & CO., LTD. (JP) | 2026-04-02 | — | — | US | disclosed |
| US-12521375-B2 | Pharmaceutical composition for treating fatty liver disease | SHIONOGI & CO., LTD. (JP) | 2026-01-13 | — | — | US | disclosed |
| US-20250257072-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | SHIONOGI & CO., LTD. (JP) | 2025-08-14 | — | — | US | disclosed |
| CN-113717198-B | Process for preparing substituted polycyclic pyridone derivatives and crystals thereof | 盐野义制药株式会社 | 2025-03-07 | — | — | CN | disclosed |
| US-20250041279-A1 | THERAPEUTIC MEDICINE FOR HEART DISEASE OR SKELETAL MUSCLE DISEASE | SHIONOGI & CO., LTD. (JP) | 2025-02-06 | — | — | US | disclosed |
| CN-112313238-B | Tetrahydropyranoxazine derivatives with selective BACE1 inhibiting activity | 盐野义制药株式会社 | 2025-01-17 | — | — | CN | disclosed |
| EP-4458348-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | Shionogi & Co., Ltd (JP) | 2024-11-06 | — | — | EP | disclosed |
| US-20240327424-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO (JP) | 2024-10-03 | — | — | US | disclosed |
| EP-4434520-A1 | PHARMACEUTICAL FOR TREATING HEART DISEASE OR SKELETAL MUSCLE DISEASE | Shionogi & Co., Ltd. (JP) | 2024-09-25 | — | — | EP | disclosed |
| US-12098151-B2 | Arenavirus growth inhibitor comprising polycyclic carbamoyl pyridone derivative | NATIONAL UNIVERSITY COPORATION HOKKAIDO UNIVERSITY (JP) | 2024-09-24 | — | — | US | disclosed |
| WO-2006122926-A1 | SUBSTITUTED AMINOPROPENYL PIPERIDINE OR MORPHOLINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006010750-A1 | SUBSTITUTED INDOLYL ALKYL AMINO DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-02 | — | — | WO | disclosed |
| US-20050171347-A1 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-04 | — | — | US | disclosed |
| EP-1549292-A2 | PHARMACEUTICAL PREPARATIONS, USE OF SAID PREPARATIONS AND METHOD FOR INCREASING THE BIOAVAILABILITY OF MEDICAMENTS FOR PERORAL ADMINISTRATION | Schering Aktiengesellschaft (DE) | 2005-07-06 | — | — | EP | disclosed |
| US-20050113373-A1 | medicine to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a histone deactylase (HDAC) in a biological sample | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-26 | — | — | US | disclosed |
| EP-1485365-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-15 | — | — | EP | disclosed |
| EP-1485354-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004032897-A2 | PHARMACEUTICAL PREPARATIONS, USE OF SAID PREPARATIONS AND METHOD FOR INCREASING THE BIOAVAILABILITY OF MEDICAMENTS FOR PERORAL ADMINISTRATION | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003076401-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003076422-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171347-A1 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | AR 1042/4885SLC16A3 2007/4885MAOB 916/4885 |
| US-20240327424-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | C3AR1, NR4A1, HAVCR2 | AR 916/4885SLC16A3 1172/4885MAOB 183/4885 |
| US-12098151-B2 | Arenavirus growth inhibitor comprising polycyclic carbamoyl pyridone derivative | CDK7, CCNA1, CCR10 | AR 2125/4885SLC16A3 3772/4885MAOB 3019/4885 |
| US-20050113373-A1 | medicine to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a histone deactylase (HDAC) in a biological sample | HDAC1, HDAC11, HDAC4 | AR 588/4885SLC16A3 3025/4885MAOB 454/4885 |
| US-20250257072-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | C3AR1, CYP4B1, ADORA2B | AR 1867/4885SLC16A3 1235/4885MAOB 89/4885 |
| US-20250041279-A1 | THERAPEUTIC MEDICINE FOR HEART DISEASE OR SKELETAL MUSCLE DISEASE | TNNT2, CPT1B, TNNC1 | AR 2471/4885SLC16A3 2929/4885MAOB 4360/4885 |
| US-20260091022-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING FATTY LIVER DISEASE | SLC10A1, GLP1R, SLC10A2 | AR 830/4885SLC16A3 225/4885MAOB 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.